IE810036L - Sustained release compositions - Google Patents

Sustained release compositions

Info

Publication number
IE810036L
IE810036L IE810036A IE3681A IE810036L IE 810036 L IE810036 L IE 810036L IE 810036 A IE810036 A IE 810036A IE 3681 A IE3681 A IE 3681A IE 810036 L IE810036 L IE 810036L
Authority
IE
Ireland
Prior art keywords
amount
milligrams
release controlling
agent
controlling agent
Prior art date
Application number
IE810036A
Other versions
IE50806B1 (en
Original Assignee
Boots Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/194,453 external-priority patent/US4308251A/en
Application filed by Boots Co Ltd filed Critical Boots Co Ltd
Publication of IE810036L publication Critical patent/IE810036L/en
Publication of IE50806B1 publication Critical patent/IE50806B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A sustained release pharmaceutical composition in table-t form comprises an effective amount of an orallyactive therapeutic agent, 0.8 to 1. 6% by weight of a release controlling agent and 1.0 to 7.5% by weight of an erosion promoting agent, the relative amounts of the components being such that a criticality factor calculated according to equation I lies in the range 20 to 450. Equation 1 is <IMG> I wherein CF is the criticality factor, CA is the. amount of therapeutic agent per tablet in milligrams divided by the amount of release controlling agent per tablet in milligrams and CS is the amount of erosion promoting agent per tablet in milligrams divided by the amount of release controlling agent per-tablet in milligrams, Suitable therapeutic agents include acetylsalicylic acid, ibuprofen and flurbiprofen. A preferred release controlling agent is cellulose acetate phthalate and a preferred erosion promoting agent is corn starch. [CA1140466A]
IE36/81A 1980-01-11 1981-01-09 Pharmaceutical compositions IE50806B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11143080A 1980-01-11 1980-01-11
US06/194,453 US4308251A (en) 1980-01-11 1980-10-17 Controlled release formulations of orally-active medicaments

Publications (2)

Publication Number Publication Date
IE810036L true IE810036L (en) 1981-07-11
IE50806B1 IE50806B1 (en) 1986-07-23

Family

ID=26808896

Family Applications (1)

Application Number Title Priority Date Filing Date
IE36/81A IE50806B1 (en) 1980-01-11 1981-01-09 Pharmaceutical compositions

Country Status (22)

Country Link
JP (1) JPS56103110A (en)
AT (1) AT374681B (en)
AU (1) AU542824B2 (en)
BE (1) BE886998A (en)
CA (1) CA1140466A (en)
CH (1) CH646604A5 (en)
DE (1) DE3100191A1 (en)
DK (1) DK6181A (en)
ES (2) ES498369A0 (en)
FI (1) FI76927C (en)
FR (1) FR2473308B1 (en)
GB (1) GB2067072B (en)
GR (1) GR73843B (en)
IE (1) IE50806B1 (en)
IN (1) IN151913B (en)
IT (1) IT1221041B (en)
LU (1) LU83052A1 (en)
NL (1) NL8100037A (en)
NO (1) NO156153C (en)
NZ (1) NZ195933A (en)
SE (1) SE447450B (en)
ZA (1) ZA81136B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2496082A (en) * 1947-05-24 1950-01-31 Ashenfelter William Scaffold structure
IT1144911B (en) * 1981-03-19 1986-10-29 Pharmatec Spa CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN
JPS59227817A (en) * 1983-06-07 1984-12-21 Toyo Jozo Co Ltd Long-acting bredinin preparation for oral administration
JPH0662404B2 (en) * 1983-06-14 1994-08-17 シンテックス・ファーマシユーテイカルズ・インターナシヨナル・リミテツド Controlled-release naproxen and naproxen sodium tablets
ZA836030B (en) * 1983-08-16 1985-02-27 Verex Lab Constant order release solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
ZA836031B (en) * 1983-08-16 1985-02-27 Verex Lab Constant release rate solid dosage theophylline formulation
EP0138216B1 (en) * 1983-10-14 1993-01-07 Sumitomo Pharmaceuticals Company, Limited Sustained-release ifn preparation for parenteral administration
US4855134A (en) * 1983-10-14 1989-08-08 Sumitomo Pharmaceuticals Company, Limited Sustained-release preparation
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
ATE87469T1 (en) * 1985-12-27 1993-04-15 Sumitomo Pharma PROCESS FOR THE MANUFACTURE OF A DELAYED RELEASE FORMULATION.
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
ZA881301B (en) * 1987-02-27 1989-10-25 Lilly Co Eli Sustained release matrix formulations
US5855915A (en) 1995-06-30 1999-01-05 Baylor University Tablets or biologically acceptable implants for long-term antiinflammatory drug release

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953497A (en) * 1953-06-03 1960-09-20 Howard A Press Therapeutic tablets
NL128902C (en) * 1960-06-06
US3577514A (en) * 1968-06-10 1971-05-04 Pfizer Sustained release pharmaceutical tablets
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
US3906086A (en) * 1971-07-19 1975-09-16 Richard G Powers Timed-release aspirin
GB1500300A (en) * 1975-01-06 1978-02-08 Ciba Geigy Ag Pharmaceutical preparation for the treatment of circulatory disorders
JPS5411226A (en) * 1977-06-24 1979-01-27 Shin Etsu Chem Co Ltd Disintegratable granule

Also Published As

Publication number Publication date
AU542824B2 (en) 1985-03-14
ES509179A0 (en) 1982-12-16
FI76927B (en) 1988-09-30
FR2473308B1 (en) 1985-07-19
ES8205353A1 (en) 1982-06-01
CA1140466A (en) 1983-02-01
NO156153B (en) 1987-04-27
CH646604A5 (en) 1984-12-14
ATA5481A (en) 1983-10-15
NO810062L (en) 1981-07-13
FI76927C (en) 1989-01-10
SE8100104L (en) 1981-07-12
NZ195933A (en) 1982-11-23
DE3100191C2 (en) 1988-09-01
IE50806B1 (en) 1986-07-23
DE3100191A1 (en) 1981-12-10
AU6597681A (en) 1981-07-16
ZA81136B (en) 1982-01-27
IN151913B (en) 1983-09-03
GB2067072B (en) 1983-08-10
ES8301629A1 (en) 1982-12-16
IT1221041B (en) 1990-06-21
GR73843B (en) 1984-05-07
IT8147537A0 (en) 1981-01-09
JPS56103110A (en) 1981-08-18
LU83052A1 (en) 1982-09-10
NL8100037A (en) 1981-08-03
BE886998A (en) 1981-07-08
GB2067072A (en) 1981-07-22
FR2473308A1 (en) 1981-07-17
ES498369A0 (en) 1982-06-01
FI810056L (en) 1981-07-12
NO156153C (en) 1987-08-05
SE447450B (en) 1986-11-17
DK6181A (en) 1981-07-12
AT374681B (en) 1984-05-25

Similar Documents

Publication Publication Date Title
IE810036L (en) Sustained release compositions
CA2009890A1 (en) Valproic acid
JPS55153715A (en) Prolonged granule of theophylline
IE791172L (en) Pharmaceutical compositions containing urea
DE59209706D1 (en) Medicines containing S (+) - ibuprofen
FR2698788B1 (en) Effervescent pharmaceutical composition containing ibuprofen and process for its preparation.
ES8502334A1 (en) Elastase-containing composition permitting elastase to be absorbed in increased amount.
MY104010A (en) Pharmaceutical compositions.
IE45439L (en) Penicillanic acid derivatives
ES8605975A1 (en) Controlled release liquid dosage formulations for pharmaceuticals.
IE781032L (en) Pharmaceutical compositions
GB1353635A (en) Coating composition for moist surfaces
TW350772B (en) Tablets with improved bioavailability of the active material clodronic acid
ES8705763A1 (en) Pharmaceutical compositions containing gels.
FR2490491B1 (en) ANALGESIC PHARMACEUTICAL COMPOSITION CONTAINING AS ACTIVE INGREDIENT 3-AMINO-2-HYDROXY-4 PHENYLBUTANOIC ACID AND DERIVATIVES THEREOF AND APPLICATION
IL65922A0 (en) Preparation of apovincaminic acid esters,certain novel optically active derivatives thereof and pharmaceutical compositions containing them
DE3160595D1 (en) Polyprenyl carboxylic acid derivatives, process for the preparation of the same, and pharmaceutical compositions
IL102949A (en) Substituted mandelic acid derivatives their preparation and pharmaceutical compositions containing them
US3035987A (en) Method of increasing the water vapor porosity of fat materials
GB1381426A (en) Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents
ES8304992A1 (en) Bis-esters of alkanediols, pharmaceutical compositions thereof and intermediates therefor.
CA2078885A1 (en) Pharmaceutical compositions containing amethocaine
JPS5750914A (en) Betamethasone external pharmaceutical
ATE16100T1 (en) ESTERS OF 1-METHYL-5-P-TOLUOYLPYRROLYL-2ACETIC ACID WITH ANTI-INFLAMMATORY, MUCOLYTIC AND ANTI-TUSSIVE PROPERTIES, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DE3166825D1 (en) Process for manufacture of a coated acetylsalicylic-acid formulation